FY2025 · ended Dec 31, 2025 · Revenue $6,000, -45.5% YoY · Filed Mar 20, 2026
Creative Medical Technology Holdings, Inc. (CELZ) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $6,000 and a net loss of $6.0 million.
Revenue (TTM)
$3,000
-50.0% vs year-ago TTM
Net income (TTM)
$-6.04M
-4.8% vs year-ago TTM
Operating cash flow (TTM)
$-5.90M
-3.8% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.96
Dividend per share
None
Shares outstanding
3.70M
+43.0% vs prior year
Net cash
$-479,553
FY 2017
Operating margin
-208004.4%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CELZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Phoenix, AZ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1187953
- Former names
- JOLLEY MARKETING INC (until May 13, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6,000 | $11,000 | $9,000 | $88,600 | $87,754 |
| Operating income | -$6.1M | -$5.7M | -$5.6M | -$10.2M | -$3.1M |
| Net income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M |
| Diluted EPS | -$2.52 | -$3.71 | — | -$0.93 | $5.61 |
| Operating cash flow | -$5.9M | -$5.3M | -$8.0M | -$7.8M | -$2.2M |
| Total assets | $7.8M | $6.7M | $10.7M | $19.2M | $11.3M |
| Total liabilities | $284,880 | $327,644 | $371,394 | $3.3M | — |
| Stockholders' equity | $7.5M | $6.3M | $10.3M | $15.9M | $10.2M |
| Cash and investments | $7.2M | $5.9M | $3.5M | $8.3M | $10.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 31, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Jul 2, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 24, 2026 | Dec 31, 2025 |
All 409 Creative Medical Technology Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.